Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Filter our case studies by categories, selecting amongst our broad range of solutions.
Global expansion and a reduction in approval timelines
ICON’s Regulatory Project Management (RPM) team was approached by a client to help establish a global footprint and reduce the approval timelines for the first wave of targeted countries located in the US, Europe, and Asia Pacific.
Automated conversion and load, including manual enrichment
ICON was asked to support a client with migrating data from an existing Regulatory Information Management (RIM) system into a new system. During migration, the ICON team needed to ensure the safety reporting requirements were correctly described in the new system as current data were incorrect and/or incomplete.
Regulatory project management scenario planning (Oncology)
ICON was asked to provide scenario planning related to accelerating the marketing authorisation application (MAA) approval through various clock-stop scenarios.
EDMS (Electronic Document Management System) expanded to a newly acquired business unit
Following a corporate acquisition, the ICON Regulatory Technology & Information Management (RTIM) team was engaged by a mid-sized life sciences company to re-design, configure, and deploy the existing EDMS to a new business unit.
XEVMPD/SPOR Compliance
The European Medicines Agency (EMA) is in the process of implementing IDMP standards that specify standardized definitions to identify and describe medicinal products for human use only.
Regulatory Guidance for Established Products
A top-10, multinational pharmaceutical company needed to enhance product support and improve its in-house development.
.jpg?crop=yes&w=2016&h=1060&a=0,142&itok=jRFSgrUq "Boardroom discussion of research"){kind=icon}
Investigational New Drug (IND) Application
A small company, with limited internal resources, was planning to submit two new INDs and reached out to ICON to help manage the IND filings.
Clinical trial with combination product and medical devices
ICON provided regulatory support for a study to develop a novel treatment for patients using an implantable combination product and three separate medical devices.
Combined study with in vitro device investigating an oncology treatment
A study sponsor was investigating a biological treatment for oncology patients in addition to the standard of care chemotherapy. They sought regulatory support from ICON due to the study’s complexity, the geographic span and because the IVD was used out of its intended purpose.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
IRT User Acceptance Testing
Resolving critical issues and ensuring trial integrity
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=OmkWAj1n "Doctor-patient interaction in study"){kind=icon}
Regulatory Strategy in Clinical Development (EU)
"A large pharma customer sought expert regulatory support from ICON for a paediatric rare disease development
program."
program."
Let's collaborate
Discover how ICON's expertise transforms clinical trials.